SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-23-008645 to International General Insurance Holdings Ltd. (IGIC) (CIK 0001794338) (IGIC)

International General Insurance Holdings Ltd. (IGIC) (CIK 0001794338)
Date: Aug. 9, 2023 · CIK: 0001794338 · Accession: 0000000000-23-008645

AI Filing Summary & Sentiment

Date
August 9, 2023
Author
Not clearly detected
Form
UPLOAD
Company
International General Insurance Holdings Ltd. (IGIC) (CIK 0001794338)

Letter

United States securities and exchange commission logo August 9, 2023 Michael Levitt Partner Freshfields Bruckhaus Deringer US LLP 601 Lexington Avenue New York, NY 10022 Re:International General Insurance Holdings Ltd. 74 Abdel Hamid Sharaf Street, P.O. Box 941428 Amman 11194, Jordan Dear Michael Levitt: We have reviewed your filing and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure. Please respond to these comments by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comments apply to your facts and circumstances, please tell us why in your response. After reviewing your response to these comments, we may have additional comments. Defined terms used herein have the same meaning as in your filing. Schedule TO-I filed July 28, 2023 General 1.We note your reference to Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Note that the safe harbor protections for forward- looking statements contained in those federal securities laws do not apply to statements made in connection with a tender offer. See Section 21E(b)(2)(C) of the Securities Exchange Act of 1934. Please delete the reference or clarify that it is not applicable to the tender offer. 2.In your response letter, please explain why this issuer tender offer is not subject to Rule 13e-3. We note that it is an offer for all outstanding Warrants, and that the Public Warrants currently trade on the Nasdaq. To the extent that Warrants are not tendered but the offer is consummated, the remaining Warrants will be subject to mandatory redemption at a reduced price as compared to the offer price. In the alternative, please file and disseminate a Schedule 13E-3.

FirstName LastNameMichael Levitt Comapany NameFreshfields Bruckhaus Deringer US LLP August 9, 2023 Page 2 FirstName LastName Michael Levitt Freshfields Bruckhaus Deringer US LLP August 9, 2023 Page 2 Security Ownership of Certain Beneficial Owners and Management, page 14 3.Please revise the table showing the number of Common Shares beneficially owned by directors and executive officers to include the aggregate number and percentage of Private Warrants and Public Warrants held by each such person. See Item 1008(a) of Regulation M-A. Conditions; Termination; Waivers; Extensions; Amendments, page 16 4.The cross reference in Item 7(b) to Section 10 of the Offer Letter appears to be inappropriate, as Section 10 sets forth the conditions to the consummation of the Offer rather than any material conditions to any financing of consideration to be provided in the Offer. See Item 1007(b) of Regulation M-A. Please revise. We remind you that the filing persons are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please direct any questions to Christina Chalk at (202) 551-3263 or Blake Grady at (202) 551-8573. Sincerely, Division of Corporation Finance Office of Mergers & Acquisitions

Show Raw Text
United States securities and exchange commission logo
August 9, 2023
Michael Levitt
Partner
Freshfields Bruckhaus Deringer US LLP
601 Lexington Avenue
New York, NY 10022
Re:International General Insurance Holdings Ltd.
74 Abdel Hamid Sharaf Street, P.O. Box 941428
Amman 11194, Jordan
Dear Michael Levitt:
            We have reviewed your filing and have the following comments. In some of our
comments, we may ask you to provide us with information so we may better understand your
disclosure.
            Please respond to these comments by providing the requested information or advise us as
soon as possible when you will respond. If you do not believe our comments apply to your facts
and circumstances, please tell us why in your response.
            After reviewing your response to these comments, we may have additional comments.
Defined terms used herein have the same meaning as in your filing.
Schedule TO-I filed July 28, 2023
General
1.We note your reference to Section 27A of the Securities Act of 1933 and Section 21E of
the Securities Exchange Act of 1934.  Note that the safe harbor protections for forward-
looking statements contained in those federal securities laws do not apply to statements
made in connection with a tender offer.  See Section 21E(b)(2)(C) of the Securities
Exchange Act of 1934.  Please delete the reference or clarify that it is not applicable to the
tender offer.
2.In your response letter, please explain why this issuer tender offer is not subject to Rule
13e-3.  We note that it is an offer for all outstanding Warrants, and that the Public
Warrants currently trade on the Nasdaq.  To the extent that Warrants are not tendered but
the offer is consummated, the remaining Warrants will be subject to mandatory
redemption at a reduced price as compared to the offer price.  In the alternative, please file
and disseminate a Schedule 13E-3.

 FirstName LastNameMichael Levitt
 Comapany NameFreshfields Bruckhaus Deringer US LLP
 August 9, 2023 Page 2
 FirstName LastName
Michael Levitt
Freshfields Bruckhaus Deringer US LLP
August 9, 2023
Page 2
Security Ownership of Certain Beneficial Owners and Management, page 14
3.Please revise the table showing the number of Common Shares beneficially owned by
directors and executive officers to include the aggregate number and percentage of Private
Warrants and Public Warrants held by each such person.  See Item 1008(a) of Regulation
M-A.
Conditions; Termination; Waivers; Extensions; Amendments, page 16
4.The cross reference in Item 7(b) to Section 10 of the Offer Letter appears to be
inappropriate, as Section 10 sets forth the conditions to the consummation of the Offer
rather than any material conditions to any financing of consideration to be provided in the
Offer.  See Item 1007(b) of Regulation M-A.  Please revise.
            We remind you that the filing persons are responsible for the accuracy and adequacy of
their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please direct any questions to Christina Chalk at (202) 551-3263 or Blake Grady at (202)
551-8573.
Sincerely,
Division of Corporation Finance
Office of Mergers & Acquisitions